These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21805610)

  • 1. Drug eluting or bare metal stents in cardiac allograft vasculopathy: the role of oral sirolimus.
    Mieres J; Fernandez-Pereira C; Rodriguez-Granillo AM; Rodriguez AE
    Catheter Cardiovasc Interv; 2012 Feb; 79(3):496; author reply 497. PubMed ID: 21805610
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature.
    Dasari TW; Hennebry TA; Hanna EB; Saucedo JF
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):962-9. PubMed ID: 21413135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy.
    Lee MS; Kobashigawa J; Tobis J
    JACC Cardiovasc Interv; 2008 Dec; 1(6):710-5. PubMed ID: 19463388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing long-term outcomes between drug-eluting and bare-metal stents in the treatment of cardiac allograft vasculopathy.
    Nfor T; Ansaarie I; Gupta A; Bajwa T; Allaqaband S
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):543-9. PubMed ID: 19405161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
    Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
    JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stent implantation for the treatment of cardiac transplant vasculopathy: the jury is still out.
    Belardi JA
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):970-1. PubMed ID: 21598349
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of clinical benefit of drug-eluting compared to bare-metal stents for treatment of transplant coronary artery disease: why we do not need drug-eluting stents?
    Fernandez-Pereira C; Mieres J; Rodriguez AE
    Catheter Cardiovasc Interv; 2013 Aug; 82(2):237. PubMed ID: 23073903
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute and long-term outcomes of ostial stentings among bare-metal stents, sirolimus-eluting stents, and paclitaxel-eluting stents.
    Hsieh IC; Hsieh MJ; Chang SH; Wang CY; Lee CH; Lin FC; Chen CC
    Coron Artery Dis; 2013 May; 24(3):224-30. PubMed ID: 23571311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus-eluting stent fractures leading to restenosis in cardiac allograft vasculopathy.
    Cilingiroglu M; Chilakapati V; Dunlap S; Leesar MA
    Cardiovasc Revasc Med; 2010; 11(2):120-3. PubMed ID: 20347805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study on provisional stenting with sirolimus-eluting stent vs. bare metal stent for the treatment of true coronary bifurcations: the PROSUMER (PROvisional with sirolimus-eluting vs. bare metal stents in truE bifuRcations) study.
    Tanzilli G; Pelliccia F; Pasceri V; Speciale G; Greco C; Arrivi A; Viceconte N; Mangieri E; Gaudio C
    Int J Cardiol; 2011 Jan; 146(2):240-1. PubMed ID: 21093942
    [No Abstract]   [Full Text] [Related]  

  • 12. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis.
    Zamani P; Kinlay S
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):202-12. PubMed ID: 20824754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bare-metal versus drug-eluting stent placement among patients presenting with anemia.
    Koul S; Moliterno DJ
    JACC Cardiovasc Interv; 2009 Apr; 2(4):337-8. PubMed ID: 19463446
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case Report of Drug-Eluting Balloon as a New Treatment Option for Cardiac Allograft Vasculopathy.
    Gulin D; Galic E; Sikic J
    Prog Transplant; 2018 Jun; 28(2):189-190. PubMed ID: 29595082
    [No Abstract]   [Full Text] [Related]  

  • 18. Sirolimus- versus paclitaxel-eluting stents for the treatment of cardiac allograft vasculopathy.
    Lee MS; Tarantini G; Xhaxho J; Yang T; Ehdaie A; Bhatia R; Favaretto E; Tobis J
    JACC Cardiovasc Interv; 2010 Apr; 3(4):378-82. PubMed ID: 20398863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Eluting Balloons-A New Tool in the Treatment of Cardiac Allograft Vasculopathy: A Case Series.
    Skoric B; Bulum J; Cikes M; Jurin H; Lovric D; Ljubas-Macek J; Samardzic J; Pasalic M; Milicic D
    Transplant Proc; 2017 Sep; 49(7):1675-1677. PubMed ID: 28838462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.